WHO ICTRP trial
Cilostazol in the treatment of schizophrenia
IRCT201407151556N61 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT201407151556N61 |
|---|---|
| Public title | Cilostazol in the treatment of schizophrenia |
| Scientific title | Cilostazol as an add-on therapy in men with chronic schizophrenia: a randomized double blind and placebo controlled trial |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | schizophrenia. schizophrenia;schizophrenia |
| Interventions | Intervention 1: Tablet Risperidone (6 mg/day) combined with 50 mg/daycilostazol as intervention group for 8 weeks. Intervention 2: Tablet Risperidone (6 mg/day) combined with placebo as control group for 8 weeks.;Treatment… |
| Registration date | Jul 17, 2014 |
| Target size | 50 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: